Skip to content

Bicara Therapeutics BCAX Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-32.3%-1.5pp-30.9%-4.2pp-26.6%
Return on assets-30.5%-1.2pp-29.3%-3.7pp-25.6%
Liquidity
Current ratio13.9×-0.7×14.6×+0.4×14.1×-11.7×25.8×+1.2×24.6×-3.3×
Quick ratio13.9×-0.7×14.6×+0.4×14.1×-11.7×25.8×+1.2×24.6×-3.3×
Cash ratio8.2×+4.9×3.3×-4.8×8.2×-17.2×25.3×+1.2×24.2×-3.1×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$8.46+15.3%$7.34-0.5%$7.38-7.5%$7.98-5.3%$8.43-71.2%
Valuation
Market capitalization$1.29B+39.8%$921.98M+7.0%$861.55M+66.1%$518.64M-27.0%$710.44M-25.1%
Enterprise value$966.81M+16.9%$827.01M+19.5%$691.85M+721%$84.27M-66.2%$248.96M-45.8%
Price / book2.5×+0.2×2.3×+0.2×2.1×+0.9×1.2×-0.4×1.5×-0.4×
Free cash flow yield-9%+2.6pp-11.6%+1.5pp-13.1%+6.4pp-19.5%-7.0pp-12.4%-4.5pp
Earnings yield-12.2%+2.8pp-15%-0.9pp-14.1%+5.7pp-19.8%-6.8pp-13%-5.8pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Bicara Therapeutics's ratios come from?
Every ratio is computed from Bicara Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.